ACET compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

ACETAdicet Bio, Inc.

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

ACETAdicet Bio, Inc.

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ACET1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±39.1%▼−13.43%×0.34

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

= impliedACET realized, solidPRLD realized, hatchedOne scale, both sides: full bar = 40%× = |realized| ÷ impliedSource: market data

ACETAdicet Bio, Inc.

3.20· pre 4.01· delayed

Mkt cap$30.0MRevenue—

PRLDPrelude Therapeutics Inc

3.84· pre 3.84· delayed

Pre-marketNov 3 '26delayed

Mkt cap$306.4MRevenue$6MQ2 FY26

Compare

Pre-marketNov 3 '26delayed

ACETAdicet Bio, Inc.

PRLDPrelude Therapeutics Inc

3.20pre 4.01delayed

Price

3.84pre 3.84delayed

$30.0M

Mkt cap

$306.4M

—

Revenue

$6MQ2 FY26

ACET3.20vsPRLD3.84Pre-marketNov 3 '26delayed